Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + vinorelbine
- Development stage
- Phase 2
- Lead developer
- EveRidge Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination regimen of pyrotinib and vinorelbine used for the treatment of HER2-positive advanced breast cancer. Pyrotinib is a novel oral tyrosine kinase inhibitor that irreversibly binds to ATP binding sites in HER1, HER2, and HER4 intracellular segments, blocking activation of key signaling pathways. Vinorelbine is a semi-synthetic, antimitotic, microtubule destabilizing drug available in both oral and intravenous formulations. This combination has shown promising efficacy and tolerable toxicity, particularly as a second-line treatment for patients who have progressed after trastuzumab therapy.
- Brand names
- AiRuiNi
- Other names
- SHR-1258SHR1258SHR 1258vinorelbine tartrate
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)MicrotubuleEGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pyrotinib + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + vinorelbine.